Envoy Medical Appoints McKhann After $1.16B, $615M Exits; Acclaim® Trial Complete
Envoy Medical has named med tech veteran Chas McKhann, whose past leadership contributed to Silk Road Medical’s $1.16B sale and Apollo Endosurgery’s $615M acquisition, to its board of directors. With pivotal trial enrollment for its FDA-designated Breakthrough Acclaim® cochlear implant now complete, McKhann will spearhead commercialization strategy.
1. Board Appointment
Envoy Medical has appointed Chas McKhann to its Board of Directors and Compensation Committee, bringing his strategic leadership to the company. As a board member, he will guide corporate governance and executive compensation decisions.
2. Med Tech Leadership and Exits
McKhann most recently served as CEO of Silk Road Medical and Apollo Endosurgery, leading to respective sales to Boston Scientific for $1.16B and $615M. His prior roles include Chief Commercial Officer positions at Torax Medical and Intersect ENT before their acquisitions by Johnson & Johnson and Medtronic.
3. Acclaim® Commercialization Strategy
With enrollment complete in the Acclaim® cochlear implant pivotal trial, McKhann will spearhead the commercialization strategy for the first-of-its-kind fully implanted device. The implant, granted FDA Breakthrough Device Designation, aims to transform treatment for adults with severe to profound hearing loss.